Pharmacoresistance in epilepsy: How should it be defined

CNS Drugs

Volumn 10, Issue 3, 1998, Pages 171-179

  Perucca, Emilio ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT;

ANTICONVULSANT THERAPY; EPILEPSY; HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE;

EID: 0031721247     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199810030-00002     Document Type: Review

References (72)

1. Kale R. Bringing epilepsy out of the shadows. BMJ 1997; 315: 2-3
2. Beghi E, Perucca E. The management of epilepsy in the 1990s: acquisitions, uncertainties, and perspectives for future research. Drugs 1995; 49: 680-94
3. National Institutes of Health Consensus Conference. Surgery for epilepsy. JAMA 1990; 264: 729-33
4. Perucca E. Principles of drug treatment. In: Shorvon S, Dreifuss F, Fish D, et al., editors. The treatment of epilepsy. Oxford: Blackwell Science, 1996: 152-68
5. Shorvon SD. The epidemiology and treatment of chronic and refractory epilepsy. Epilepsia 1996; 37 Suppl. 2: 1-3
6. Pedley TA. The challenge of intractable epilepsy. In: Chadwick D, editor. New trends in epilepsy management: the role of gabapentin. London: Royal Society of Medicine, 1993: 3-12
7. Jaillon P. The problem of intractability: the continuing need for new medical therapies in epilepsy. Epilepsia 1997; 38 Suppl. 9: 37-42
8. Nashef L, Shorvon SD. Mortality in epilepsy. Epilepsia 1997; 38: 1059-61
9. Nakken KO. Medical risks in intractable epilepsy. In: Johannessen SI, Gram L, Sillanpaa M, et al., editors. Intractable epilepsy. Petersfield: Wrightson Biomedical Publishing Ltd., 1995: 171-82
10. Begley CE, Annegers JF, Lairson D, et al. The cost of epilepsy: a model based on incidence and prognosis. Epilepsia 1994; 35: 1230-43
11. Annegers JF, Hauser WA, Elveback LR. Remission of seizures and relapse in patients with epilepsy. Epilepsia 1979; 20: 729-37
12. Berg AT, Levy SR, Novotny EJ, et al. Predictors of intractable epilepsy in childhood: a case-control study. Epilepsia 1996; 37: 24-30
13. Camfield C, Camfield P, Gordon K, et al. Outcome of childhood epilepsy: a population-based study with a simple scoring system for those treated with medication. J Pediatr 1993; 122: 861-8
14. Juul-Jensen P. Epidemiology of intractable epilepsy. In: Schmidt D, Morselli PL, editors. Intractable epilepsy, experimental and clinical aspects. New York: Raven Press, 1986: 5-11
15. Sander JWAS. Some aspects of prognosis in the epilepsies: a review. Epilepsia 1993; 34: 1007-16
16. Sillanpaa M. Remission of seizures and prediction of intractability in long-term follow-up. Epilepsia 1993; 34: 930-6
17. Sillanpaa M. Epidemiology of intractable epilepsy in children In: Johannessen SI, Gram L, Sillanpaa M, et al., editors. Intractable epilepsy. Petersfield: Wrightson Biomedical Publishing Ltd., 1995: 13-24
18. Forsgren L. Epidemiology of intractable epilepsy in adults. In: Johannessen SI, Gram L, Sillanpaa M, et al., editors. Intractable epilepsy. Petersfield: Wrightson Biomedical Publishing Ltd., 1995: 25-40
19. Shinnar S, Berg AT. Does antiepileptic drug therapy prevent the development of 'chronic' epilepsy? Epilepsia 1996; 37: 701-8
20. Tishler DM, Weinberg KI, Hinton DR, et al. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 1995; 36: 1-6
21. Loscher W, Ebert U. Experimental models for intractable epilepsy. In: Johannessen SI, Gram L, Sillanpaa M, et al., editors. Intractable epilepsy. Petersfield: Wrightson Biomedical Publishing Ltd., 1995: 53-71
22. Reynolds EH, Elwes RDC, Shorvon SD. Why does epilepsy become intractable? Lancet 1983; II: 952-4
23. Hermanns G, Noachtar S, Tuxhorn I, et al. Systematic testing of medical intractability for carbamazepine, phenytoin, and phenobarbital or primidone in monotherapy for patients considered for epilepsy surgery. Epilepsia 1996; 37: 675-9
24. Heinemann U, Draguhn A, Ficker E, et al. Strategies for the development of drugs for pharmacoresistant epilepsies. Epilepsia 1994; 35 Suppl. 5: 10-21
25. Paetau R, Hamalainen M, Hari E, et al. Magnetoencephalographic evaluation of children and adolescents with intractable epilepsy. Epilepsia 1994; 35: 275-84
26. Duncan JS. Neuroimaging of epilepsy. In: Johannessen SI, Gram L, Sillanpaa M, et al., editors. Intractable epilepsy. Petersfield: Wrightson Biomedical Publishing Ltd., 1995: 125-52
27. Gulkdvog B, Loyning Y, Hauglie-Hanssen E, et al. Predictive factors for success in surgical treatment for partial epilepsy: a multivariate analysis. Epilepsia 1994; 35: 566-78
28. Carlson H. Epilepsy surgery: techniques, risks and results. In: Johannessen SI, Gram L, Sillanpaa M, et al., editors. Intractable epilepsy. Petersfield: Wrightson Biomedical Publishing Ltd., 1995: 221-32
29. Perucca E. Drugs under clinical trial. In: Eadie MJ, Wajda F, editors. Anticonvulsant drugs: handbook of experimental pharmacology. Berlin: Springer Verlag. In press
30. Perucca E. Definition of pharmacological intractability (drug resistance) [abstract]. Epilepsia 1997; 38 Suppl. 3: 102
31. Schachter SC. Advances in the assessment of refractory epilepsy. Epilepsia 1993; 34 Suppl. 5: 24-30
32. Schmidt D. Diagnostic and therapeutic management of intractable epilepsy. In: Schmidt D, Morselli PL, editors. Intractable epilepsy: experimental and clinical aspects. New York: Raven Press, 1986: 237-57
33. Jaillon P, Despland PA. Les epilepsies pharmaco-resistantes: épidémiologie, facteurs de risque. Med Hyg 1996; 54: 1784-6
34. Leppik IE. Intractable epilepsy in adults. In: Theodore WH, editor. Surgical treatment of epilepsy. Amsterdam: Elsevier, 1992: 7-13
35. Wolf P. New antiepileptic drugs already registered. Epilepsia 1994; 35 Suppl. 5: 22-4
36. Alving J. What is intractable epilepsy? In: Johannessen SI, Gram L, Sillanpaa M, et al., editors. Intractable epilepsy. Petersfield: Wrightson Biomedical Publishing Ltd., 1995: 1-12
37. Perucca E. The new generation of antiepileptic drugs: advantages and disadvantages. Br J Clin Pharmacol 1996; 42: 531-43
38. Schmidt D, Leppik IE. Compliance in epilepsy. Amsterdam: Elsevier, 1988
39. Cramer JA, Mattson RH, Prevey L, et al. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989; 261: 3273-7
40. Tomson T. Non-compliance and intractability of epilepsy. In: Johannessen SI, Gram L, Sillanpaa M, et al., editors. Intractable epilepsy. Petersfield: Wrightson Biomedical Publishing Ltd., 1995: 93-104
41. Perucca E, Gram L, Avanzini G, et al. Antiepileptic drugs as a cause of worsening of seizures. Epilepsia 1998; 39: 5-17
42. Binnie CD, Wens PVD. Diagnostic reevaluation by intensive monitoring of intractable absence seizures. In: Schmidt D, Morselli PL, editors. Intractable epilepsy: experimental and clinical aspects. New York: Raven Press, 1986: 99-107
43. Panayiotopoulos CP, Tahan R, Obeid T. Juvenile myoclonic epilepsy: factors of error involved in the diagnosis and treatment. Epilepsia 1991; 32: 672-6
44. Panayiotopoulos CP, Obeid T, Tahan R. Juvenile myoclonic epilepsy: a 5-year prospective study. Epilepsia 1994; 35: 285-96
45. Perucca E, Richens A. Antiepileptic drugs: clinical aspects. In: Richens A, Marks V, editors. Therapeutic drug monitoring. Edinburgh: Churchill-Livingstone, 1981: 320-48
46. Perucca E. Pharmacologic advantages of antiepileptic drug monotherapy. Epilepsia 1997; 38 Suppl. 5: 6-8
47. Riva R, Albani F, Ambrosetto G, et al. Diurnal fluctuations in free and total steady-state plasma levels of carbamazepine and correlation with intermittent side effects. Epilepsia 1984; 25: 476-81
48. Bjorn A. Psychosocial factors contributing to intractable epilepsy. In: Johannessen SI, Gram L, Sillanpaa M, et al., editors. Intractable epilepsy. Petersfield: Wrightson Biomedical Publishing Ltd., 1995: 73-91
49. Ahmad S, Laidlaw J, Houghton GW, et al. Involuntary movements caused by phenytoin intoxication in epileptic patients. J Neurol Neurosurg Psychiatry 1975; 38: 225-31
50. Brodie MJ. Tiagabine in the management of epilepsy. Epilepsia 1997; 38 Suppl. 2: 23-7
51. Fitton A, Goa KL. Lamotrigine: an update of its pharmacology and therapeutic use in epilepsy. Drugs 1995; 50: 691-713
52. Goa KL, Ross SR, Chrisp P. Lamotrigine: a review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1993; 46: 152-76
53. Goa KL, Sorkin EM. Gabapentin: a review of its pharmacological properties and clinical potential in epilepsy. Drugs 1993; 46: 409-27
54. Grant SM, Heel RC. Vigabatrin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. Drugs 1991; 41: 889-926
55. Marson AG, Kadir ZA, Chadwick DW. New antiepileptic drugs: a systematic review of their efficacy and tolerability. BMJ 1996; 313: 1169-79
56. Palmer KJ, McTavish D. Felbamate: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in epilepsy. Drugs 1993; 45: 1041-65
57. Perucca E. A pharmacological and clinical review of topiramate, a new antiepileptic drug. Pharmacol Res 1997; 35: 241-56
58. Peters DH, Sorkin EM. Zonisamide: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy. Drugs 1993; 45: 760-87
59. Brodie MJ. The drugs are not all the same. BMJ 1997; 314: 603-4
60. Walker MC, Sander JWAS. Difficulties in extrapolating from clinical trials to clinical practice: the case of antiepileptic drugs. Neurology 1997; 49: 333-7
61. De Silva M, MacArdle B, McGowan M, et al. Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy. Lancet 1996; 347: 709-13
62. Heller AJ, Chesterman P, Elwes RDC, et al. Phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed adult epilepsy: a randomised comparative monotherapy trial. J Neurol Neurosurg Psychiatry 1995; 58: 44-50
63. Richens A, Davidson DLW, Cartlidge NEF, et al. A multicentre trial of sodium valproate and carbamazepine in adult-onset epilepsy. J Neurol Neurosurg Psychiatry 1994; 57: 682-7
64. Shorvon SD, Chadwick D, Galbraith AW, et al. One drug for epilepsy. BMJ 1978; 1: 474-6
65. Verity CM, Hosking G, Easter DJ, et al. A multicentre comparative trial of sodium valproate and carbamazepine in paediatric epilepsy. Dev Med Child Neurol 1995; 37: 97-108
66. Hakkarainen H. Carbamazepine vs diphenylhydantoin vs their combination in adult epilepsy [abstract]. Neurology 1980; 30: 354
67. Tanganelli P, Regesta G. Vigabatrin versus carbamazepine monotherapy in newly diagnosed epileptics: a randomized response conditional cross-over study. Epilepsy Res 1996; 25: 257-62
68. Camfield PR, Camfield CS, Gordon K, et al. When a first medication fails to control a child's epilepsy, what are the chances of success with the next drug? Epilepsia 1997; 38 Suppl. 8: 191
69. Kramer G. The limitations of antiepileptic drug monotherapy. Epilepsia 1997; 38 Suppl. 5: 9-13
70. Sander JWAS. Long-term use of new antiepileptic drugs, lamotrigine and vigabatrin: an audit of outcome. BMJ 1996; 313: 1184-5
71. Walker MC, Sander JWAS. The impact of the new antiepileptic drugs on the prognosis of epilepsy: seizure freedom should be the ultimate goal. Neurology 1996; 46: 912-4
72. O'Donoghue MF, Sander JWAS. How rational is current antiepileptic drug treatment? Rev Neurol (Paris) 1997; 153 Suppl. 1: 25-8